feed,title,long_url,short_url
Benzinga,5 Value Stocks In The Basic Materials Sector,https://benzinga.com/news/21/06/21528820/5-value-stocks-in-the-basic-materials-sector,https://j.mp/2RQ5Itq
Benzinga,Target Hospitality Insights: Return On Capital Employed,https://benzinga.com/news/21/06/21528833/target-hospitality-insights-return-on-capital-employed,https://j.mp/3gt48Wu
Benzinga,Nordson Insights: Return On Capital Employed,https://benzinga.com/news/21/06/21528829/nordson-insights-return-on-capital-employed,https://j.mp/3gx6WlI
Benzinga,Return On Capital Employed Overview: RBC Bearings,https://benzinga.com/news/21/06/21528817/return-on-capital-employed-overview-rbc-bearings,https://j.mp/2TPX52q
Benzinga,Return On Capital Employed Overview: VF,https://benzinga.com/news/21/06/21528806/return-on-capital-employed-overview-vf,https://j.mp/3gqIWAt
Benzinga,Booz Allen Hamilton: Return On Capital Employed Insights,https://benzinga.com/news/21/06/21528774/booz-allen-hamilton-return-on-capital-employed-insights,https://j.mp/3cAoHiG
Benzinga,Foot Locker Insights: Return On Capital Employed,https://benzinga.com/news/21/06/21528772/foot-locker-insights-return-on-capital-employed,https://j.mp/3goOhs9
Benzinga,Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial,https://benzinga.com/general/biotech/21/06/21527732/curis-shares-drop-after-updated-ca-4948-data-from-mid-stage-blood-cancer-trial,https://j.mp/3iE5yQH
Benzinga,Deere Insights: Return On Capital Employed,https://benzinga.com/news/21/06/21528768/deere-insights-return-on-capital-employed,https://j.mp/3wfxvCd
Benzinga,Hawkins Insights: Return On Capital Employed,https://benzinga.com/news/21/06/21528762/hawkins-insights-return-on-capital-employed,https://j.mp/3ggJtX0
Benzinga,Looking Into Chipotle Mexican Grill's Return On Capital Employed,https://benzinga.com/news/21/06/21528756/looking-into-chipotle-mexican-grills-return-on-capital-employed,https://j.mp/3geadXZ
Benzinga,"Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients",https://benzinga.com/news/21/06/21527413/equilliums-itolizumab-shows-rapid-durable-responses-in-graft-versus-host-disease-patients,https://j.mp/3cAHb2C
Benzinga,Return On Capital Employed Overview: ePlus,https://benzinga.com/news/21/06/21528747/return-on-capital-employed-overview-eplus,https://j.mp/3gbC7nx
